A global MedTech Company, Meril Life Sciences is a worldwide medical device manufacturer. This company represents best-in-class medical devices. On 6 July 2019, MeRes100 BRS’s indigenously manufactured and designed scaffold declared by the Meril Life Sciences. Which became the leading thin-strut bioresorbable scaffold to obtain CE marking. Meril’s MeRes100 got marketing approval for both DCGI and CE (European Conformity). MeRes100 is planning to be launch in numerous countries, including European countries, in succeeding year. This is supported by Intensive research and inspiring clinical trial data.
There is an indication that CVD starts to affect Indians minimal a decade before that it affects Europeans. Metallic drug-eluting stents (DES) involved a metallic platform with a coating of the drug. It has a function to deliver a drug. Just to facilitate healing and to provides provisional scaffolding to the lesion or blockage site. After completion of healing, metallic stent leftovers in the body as an enduring implant. Such metallic DES is related to the incremental risk of adverse or clinical events. Metallic DES implants of 2-3% of patients may need a repeat intervention annually. Just to bridge the gap between the undesirable permanent nature of a metallic DES implant and the temporary treatment horizon for opening a blockage. So as a solution MeRes100 was designed.
MeRes-1 and MeRes-1 Extend MeRes100 BRS has shown long-term safety and continued efficacy outcomes for patients over clinical trials. The thickness of the scaffold strut is 100 microns. It leads to quicker healing and endothelialization. Which has results in a lesser possibility of scaffold thrombosis. Both trials have endorsed this advantage. By representing zero scaffold thrombosis and quite MACE (major adverse cardiac event) rate of 1.87% in MeRes-1 Study with MeRes100 BRS at three years. As well as 1.61% MACE rate in MeRes-1 Extend Study at two years.